📅 PUBMED DAILY TRIAGE — 2026-06-11

Window: 2026-06-10T09:00:00Z → 2026-06-11T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~85 raw / 24 formally classified | Candidates evaluated: 24 High priority: 5 | Standard: 17 | Low/archive: 3 | Unsolicited finds: 1 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

🧬 Early Cancer Detection (Liquid Biopsy / ctDNA / cfDNA)

TR-2026-06-11-001 / PMID 42268298 · Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and ER Status Classification of Advanced Breast Cancer · 9/10 🔴 EARLY_CANCER_DETECTION

• Cancer Research | Princess Margaret Cancer Centre | n=79 mBC + 713-sample validation compendium (>10 cancer types)
• Why it matters: Validated multi-cohort cfDNA methylation framework (cfMeDIP-seq) enabling simultaneous breast cancer detection, tumor distinction from other malignancies, AND estrogen receptor classification from liquid biopsy — addressing the critical clinical gap in monitoring metastatic BC where serial tissue biopsies are impractical.
• DOI: 10.1158/0008-5472.CAN-26-0076

TR-2026-06-11-004 / PMID 42266691 · Non-invasive radiogenomic mapping of the SMARCAL1-driven ferroptotic niche is associated with longitudinal MRD-negative surveillance in early-stage NSCLC · 8/10 🔴 EARLY_CANCER_DETECTION

• Frontiers in Immunology | n=71 (derivation) + n=267 (external validation, 2 cohorts) | PMC open access
• Why it matters: Externally validated pre-operative CT Rad-Score (C-index 0.783–0.812) serves as non-invasive surrogate for ctDNA MRD negativity in resected NSCLC; SMARCAL1/ferroptosis mechanism CRISPR-validated; outperforms 5 established biomarker comparators; prospective trial pending (NCT05457049).
• DOI: 10.3389/fimmu.2026.1835413

🎯 Precision Oncology / Novel Therapeutics

TR-2026-06-11-002 / PMID 42268543 · Preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis: 3-year follow-up — JCOG1704 · 9/10 🟠 NOVEL_TREATMENT

• Gastric Cancer | Phase II trial | n=47 (bulky nodal/para-aortic metastasis)
• Why it matters: 3-year OS of 86.7% for a historically poor-prognosis presentation (prior standard JCOG0405: 58.8% OS), with PFS 75.6% and R0 resection rate 89.4%; JCOG community adopted DOS as provisional standard of care without requiring a Phase III trial — an exceptional level of practice-changing signal from Phase II data.
• DOI: 10.1007/s10120-026-01766-3

💊 Cardiovascular-Metabolic

TR-2026-06-11-003 / PMID 42267907 · Cardiovascular Disease Risk Among Young Adults with Disabilities: A Nationwide Cohort Study · 8/10 🟡 UNDERSERVED_POPULATION

• European Journal of Preventive Cardiology | Korean nationwide cohort | n=7,682,700 (91,500 with disability, exact 1:10 matched)
• Why it matters: Among the largest epidemiological studies ever conducted in disability-CVD intersection; quantifies independent CVD risk elevation in young adults (20–39 years) with physical, neurological, sensory, and communication disabilities — a population routinely excluded from cardiovascular prevention programs.
• DOI: 10.1093/eurjpc/zwag321

🌿 Aging / Population Health (Unsolicited Find)

TR-2026-06-11-005 / PMID 42268603 · Cost-Effectiveness of Oral Nicotinamide for Keratinocyte Carcinoma Prevention · 8/10 🟢 NEAR_TERM_IMPLEMENTABLE (unsolicited find)

• JAMA Dermatology | VHA economic cohort | n=33,822 (mean age 77 years)
• Why it matters: Oral nicotinamide for KC prevention is cost-saving at −$58,426/QALY (net savings $364K/year, 624 KCs prevented) in the largest cancer prevention analysis in veterans to date; nicotinamide is cheap, widely available, and low-risk — this economic analysis provides the missing piece for guideline adoption in high-risk elderly patients.
• DOI: 10.1001/jamadermatol.2026.1639

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic Malignancies (T1 — Best score: 7/10)

• 42268418 · ML early death prediction in PTCL-NOS, n=1156 SEER, XGBoost AUROC 0.842 · 7/10 · Diagnostics
• 42268406 · Pediatric CBF-AML multicenter n=289: KIT/FLT3-ITD don't predict survival; MRD is dominant prognostic factor · 7/10 · Diagnostics/Genomics
• 42268480 · WT1 dynamics AML/MDS post-HSCT n=51: WT1 conversion to negative predicts favorable OS/PFS · 6/10 · Diagnostics
• 42268504 · MM-VTE risk stratification n=433: optimized system AUC 0.742 vs 0.605 for IMWG · 6/10 · Prevention
• 42268556 · CD33 T-cell engager AMG 330 reanalysis: E:T ratio explains 92.4% of lysis vs 8.5% for CD33 density · 5/10 · Drug Development

Early Cancer Detection (T3 — Best score: 9/10 — covered in HIGH section)

• 42267187 · Exosomal miR-27a-5p for parathyroid carcinoma vs adenoma: n=65, good diagnostic efficacy, PIK3CA target · 6/10 · Early Detection
• 42267455 · PD-L1+ mesenchymal CTCs + PET WTLG in NSCLC on ICI: bootstrap AUC 0.821 for PFS prediction · 5/10 · Diagnostics

AI/ML in Diagnostics (T4 — Best score: 7/10)

• 42268403 · PD cortical progression subtypes by FDG-PET + MRI: n=317 + PPMI external validation, 2 subtypes · 7/10 · Diagnostics
• 42268305 · AI breast US in pregnant/lactating patients n=504 (MGH/BWH): sensitivity matched radiologists (80%), fewer BI-RADS 3 · 6/10 · Diagnostics
• 42268482 · YOLOv5/v8 breast cancer detection in DDSM mammography: mAP 0.99 for YOLOv8 · 5/10 · Diagnostics

Precision Oncology (T5 — Best score: 9/10 — covered in HIGH section)

• 42268523 · EMERALD RCT QoL: eribulin vs taxane in HER2+ MBC: time to QoL deterioration 7.16 vs 4.57 months · 6/10 · Treatment Innovation
• 42268368 · ecDNA CCND1 amplification in HNSCC: TCGA n=153, CCND1-ecDNA drives markedly worse OS · 5/10 · Genomics

Novel Therapeutics (T6 — Best score: 6/10)

• 42268420 · cDC1 biology for enhanced immunotherapy: J Exp Med review; Mount Sinai/Parker Institute; molecular, spatial, therapeutic synthesis · 6/10 · Treatment Innovation
• 42268564 · PD-L1 CPS in mTNBC pembrolizumab real-world Poland n=72: CPS not quantitatively predictive beyond threshold · 5/10 · Treatment Innovation

Cardiovascular-Metabolic (T7 — Best score: 8/10 — covered in HIGH section)

• 42267984 · GLP-1 analogs in cirrhosis (TriNetX): HR 0.374 for mortality, HR 0.554 for HRS after propensity matching · 7/10 · Treatment Innovation
• 42266955 · MAFLD predicts MACE in COPD: prospective n=168, 4-fold increased risk, highest Bayesian posterior inclusion · 5/10 · Diagnostics

Rare Diseases (T9 — Best score: 7/10)

• 42267904 · Sanjad-Sakati Syndrome international registry n=135: median survival 27.2y, 62.4% OS at 18y, respiratory failure 84% of deaths · 7/10 · Public Health
• 42267532 · MAJIQ-CLIN: RNA-seq tool for Mendelian disease splicing variant detection; outperforms existing tools, Undiagnosed Diseases Network · 6/10 · Diagnostics

💡 UNSOLICITED FINDS

TR-2026-06-11-005 / PMID 42268603 — Already listed in HIGH section above (nicotinamide KC prevention, JAMA Dermatol, 8/10). Caught via Aging/longevity topic query (elderly VHA cohort); primary category is skin cancer prevention.

TR-2026-06-11-023 / PMID 42268677 — Global NCD burden from PM2.5 in adults ≥65 (QJM, GBD 2021): 3.32M deaths, 56.3M DALYs, 125% increase 1990–2021, projected +50% to 2031. Score: 5/10. Population health / policy context.

📊 TODAY'S BREAKDOWN

By research category:

• Diagnostics: 9
• Treatment Innovation: 7
• Early Detection: 3
• Public Health/Prevention: 3
• Drug Development: 1
• Genomics/Precision Medicine: 1

By evidence maturity:

• Validated: 10
• Exploratory: 12
• Potentially Practice-Changing: 1 (JCOG1704)
• Prospective validation pending: 2 (PMID 42266691, 42267907)

By watchlist topic (reviewed / kept / highest score):

By source type: peer_reviewed: 24 | preprint: 0

Topics with zero 8+ articles this run:

• T1 Hematologic (best: 7/10)
• T4 AI/ML Diagnostics (best: 7/10)
• T6 Novel Therapeutics (best: 6/10)
• T8 Aging/longevity (42268603 captured here but primary topic = Prevention/unsolicited)

🔧 RUN NOTES

• T2 (CBC/ML) — 7th consecutive zero. Pivot query applied (clinical/longitudinal refiners, phrase "morphology AI" dropped). Still zero results. Escalation: consider dropping this topic from daily CRDT-window scanning and running as a separate weekly PubMed search with extended 7-day window, or switching to Google Scholar for this niche topic.

• T8 (Aging) — Non-human noise partially resolved. Removal of humans[MeSH] + clinical/cohort refiners reduced non-human noise (fish telomere study PMID 42268545 still slipped through). Recommend adding NOT (fish OR rat OR mouse OR zebrafish OR insect OR drosophila) as exclusion terms OR reinstate humans[MeSH] with fallback window.

• JCOG1704 (PMID 42268543) flagged as potentially practice-changing — Phase II 3-year OS 86.7% vs 58.8% historical standard; JCOG community consensus adopted this as provisional standard of care without Phase III. First gastric cancer entry scoring ≥9/10 this year. Recommend flagging for Phase 2 synthesis.

• cfDNA methylation mBC (PMID 42268298) — Strong multi-cohort validation study. First 9/10 in T3 liquid biopsy topic since PMID 42262988 on 2026-06-10. Two consecutive strong liquid biopsy days.

• Sentinel cap: 907 raw results reviewed top 10 only. High overlap with watchlist captures. No unique sentinel HIGH articles.

• Previous state dedup: All 5 HIGH articles have new PMIDs not previously emitted. All 5 Telegram alerts sent (maximum for run met).

• No preprints in today's qualifying articles. No retraction notices encountered.

• Rolling 7-day summary (from state logs): T2 CBC/ML = 0/7 days qualifying. T8 Aging = 0/7 days (with humans[MeSH]) → 1/1 day (without, if we count 42268603 as T8 adjacent). Consider T2 restructure urgently.